Assessment of metabolic abnormalities and their relations to disease severity in non-diabetic patients with Metabolic dysfunction Associated Steatotic Liver Disease (MASLD).

Abo EL-Einin Khattab, Mahmoud Mahmoud; Mady, Ahmed Mohammed; Abdelalem, Emad Allam; Abdel-Bary, Fawzeya Mohammed; Ahmed, Hebatullah Salah; Mohamed, Elham Ahmed

doi:10.21608/mjmr.2025.360369.1909

	Assessment of metabolic abnormalities and their relations to disease severity in non-diabetic patients with Metabolic dysfunction Associated Steatotic Liver Disease (MASLD).
Minia Journal of Medical Research
Articles in Press, Accepted Manuscript, Available Online from 10 March 2025
Document Type: Original Article
DOI: 10.21608/mjmr.2025.360369.1909
View on SCiNiTO
Authors
Mahmoud Mahmoud Abo EL-Einin Khattab¹; Ahmed Mohammed Mady²; Emad Allam Abdelalem³; Fawzeya Mohammed Abdel-Bary²; Hebatullah Salah Ahmed ⁴; Elham Ahmed Mohamed⁵
¹Professor of internal medicine and hepatology, Faculty of Medicine, Minia university, Egypt.
²Lecturer in internal medicine and hepatology, Faculty of Medicine, Minia university, Egypt
³Professor of clinical pathology, Faculty of Medicine, Minia University, Egypt
⁴internal medicine department, faculty of medicine, Minia university
⁵Associated Professor of Internal Medicine, Faculty of Medicine, Minia University, Egypt.
Abstract
Background: Currently, Metabolic dysfunction associated steatotic liver disease (MASLD) has an upgrowing incidence globally with increased both hepatic and non-hepatic morbidities. All morbidities are linked to advanced fibrosis stages. Prompt assessment of fibrosis stage is MASLD is crucial. Aim of the work: to evaluate metabolic abnormalities (insulin resistance & dyslipidemia) in MASLD and their relation to hepatic fibrosis. Methods: This study is a case control study. All patients were recruited from Minia University Hospital’s Hepatology and Gastroenterology outpatient clinic. 50 MASLD patients were included and 50 healthy individuals (as a control group). Clinical examination and body mass index assessment, basic laboratory investigations, metabolic parameters (HOMA-IR, lipid profile) and NFS was calculated. MASLD patients were divided according to fibrosis stage by NFS in 3 subgroups: low score, intermediate and high score. Results: MASLD patients showed significantly higher HOMA-IR (6.27 ± 2.2) than control group (0.8 ±0.47) (p <0.001). Also, significantly higher TG, TC, LDL-C values were observed in MASLD patients. High fibrosis score subgroup had significantly higher BMI, HOMA-IR. NFS had significant positive correlation with BMI (r =0.6), TG (r =0.3), HOMA-IR (r =0.29). Conclusion: We concluded that assessment of HOMA-IR and lipid profile is valuable in determination of fibrosis stage in MASLD patients.
Keywords
MASLD; insulin resistance; dyslipidemia


Statistics Article View: 93